US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

- New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis - Heart failure accounts for more than one million hospitalizations a year in the U.S. RIDGEFIELD, Conn. and INDIANAPOLIS, Aug.